| Autor: |
Papatheodoridis, G.V. Sypsa, V. Dalekos, G.N. Yurdaydin, C. Van Boemmel, F. Buti, M. Calleja, J.L. Chi, H. Goulis, J. Manolakopoulos, S. Loglio, A. Voulgaris, T. Gatselis, N. Keskin, O. Veelken, R. Lopez-Gomez, M. Hansen, B.E. Savvidou, S. Kourikou, A. Vlachogiannakos, J. Galanis, K. Idilman, R. Esteban, R. Janssen, H.L.A. Berg, T. Lampertico, P. |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the need for HCC surveillance in this setting. Methods: Of 1,951 adult Caucasians with CHB included in the PAGE-B cohort, 1,427 (73%) had completed >5 years of follow-up under therapy without developing HCC by year 5. Median follow-up was 8.4 years from treatment onset. Points-based risk scores were developed to predict HCC risk after year 5. Results: In years 5–12, HCC was diagnosed in 33/1,427 (2.3%) patients with cumulative incidences of 2.4%, 3.2% and 3.8% at 8, 10 and 12 years, respectively. Older age or age >50 years, baseline cirrhosis and liver stiffness (LSM) ≥12 kPa at year 5 were independently associated with increased HCC risk. The HCC incidence was lower in non-cirrhotics than cirrhotics at baseline with year-5 LSM |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
